Trial Profile
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 01 May 2022 Final results published in the Clinical Lymphoma, Myeloma & Leukemia.
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.